Research To Practice | Oncology Videos

Featuring an interview with Dr Matthew Lunning, including the following topics:
Bispecific antibody/antibody-drug conjugate combinations (0:00)
A man in his late 90s with mantle cell lymphoma — Ann LaCasce, MD, MMSc (8:07)
CME information and select publications

Featuring a presentation by Dr Matthew Matasar, including the following topics:
Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (0:00)
Clinician Survey Results Regarding First-Line Treatment of DLBCL (11:41)
Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL (16:01)
Clinician Survey Results Regarding the Use of Monoclonal and Bispecific Antibodies for R/R DLBCL (28:47)
Evidence-Based Incorporation of Antibody-Drug Conjugates (ADCs) into the Management of R/R DLBCL (34:34)
Clinician Survey Results Regarding the Use of ADCs for R/R DLBCL (46:31)
Discussion of Questions from the Community (50:20)
CME information and select publications

Featuring an interview with Dr Matthew Lunning, including the following topics:
A woman in her late 70s with non-GCB diffuse large B-cell lymphoma receives pola-R-CHP — Ann LaCasce, MD, MMSc (0:00)
CNS prophylaxis in non-Hodgkin lymphoma (7:58)
CME information and select publications

Featuring an interview with Dr Erica Mayer, including the following topics:
Risk Assessment and Genomic Assays for Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer (0:00)
Investigator Survey Results on Risk Assessment and Genomic Assays (20:07)
Adjuvant CDK4/6 Inhibitors for High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer (24:30)
Investigator Survey Results on Adjuvant CDK4/6 Inhibitors (30:42)
Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (32:07)
Investigator Survey Results on Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (37:44)
Adjuvant Oral Selective Estrogen Receptor Degraders (SERDs) for HR-Positive, HER2-Negative Localized Breast Cancer (39:05)
Investigator Survey Results on Adjuvant Oral SERDs (43:02)
Discussion of Questions from the Community (45:00)
CME information and select publications

Featuring perspectives from Dr Lindsey Roeker, including the following topics:
Case: A man in his mid 60s with TP53-aberrant chronic lymphocytic leukemia (CLL) with extensive marrow infiltration receives first-line venetoclax/obinutuzumab and experiences an excellent response (0:00)
Case: A man in his late 70s with small lymphocytic lymphoma (SLL) and cardiovascular comorbidities requiring verapamil and anticoagulation receives acalabrutinib/venetoclax; Case: A man in his early 80s with SLL receives zanubrutinib/sonrotoclax as part of the CELESTIAL-TNCLL trial (14:46)
Case: A man in his late 70s with progressive CLL worsening after a skiing injury receives acalabrutinib/venetoclax as part of the MAJIC trial (22:37)
CME information and select publications